10 Facts* and 41 Informed Conjectures about the Health Effects of Fluoride
Randall P. Ellis
Boston University
April 29, 2016
Please to not quote or cite.
1
*Currently 13 to be narrowed down to ten.
Ellis 64
0
0.5
1
1.5
2
2.5
3
3.5
4
0 1 2 3 4
F 2 =
Fo
od
F1 = drinking water
Two Dimensions of F Intake
Ellis 65
0
0.5
1
1.5
2
2.5
3
3.5
4
0 1 2 3 4
F 2 =
Fo
od
F1 = drinking water
Correlated Exposure Really Changes Risk.
Result #1
Water Fluoridation in Australia is associated with small but statistically significant negative impact on birth weight. Working paper: Preliminary! The Effects of Artificially Fluoridated Water on Birth Outcomes Marian Vidal-Fernandez, Denise Doiron, and Randall P. Ellis April 19, 2016 University of Sydney, UNSW, BU
Ellis 66
Ellis 67
Ellis 68
Ellis 69
Ellis 70
Ellis 71
Ellis 72
Ellis 73
Ellis 74
2010 Annual Fluoridation Report
Ellis 75
2010 Annual Fluoridation Report
Four different chemicals used in CA. Only NaF (Sodium Fluoride) was used in clinical trials.
Ellis 76
2010 Annual Fluoridation Report
Fluoride rates fluctuate meaningfully around optimum target
Ellis 77
California 2013 Annual Fluoridation Report
Latest reports omit chemical used and monthly rates.
Ellis 78
A simplified notation F model (All variables subscripted by region j and time t for individual I, but subscripts omitted unless necessary) F = Actual level of water Fluoridation in county Ftar = targeted level of Fluoride ε= error affecting level of F in water F = Ftar+ ε D = Other sources of fluoride (Drugs, food, air, pesticides), measured in units of F AEF = Acute effects of F CEF = chronic effects of F Θ = share of population in a county with F in drinking water W = quantity of water consumed β = Sensitivity to F where possibly β = 𝛽 +υ Y = any dependent variable X = set of other non F-related control variables that affect Y Y = f(F, D, Θ,W, X) Assume one county, j. Assume only one period t, and that AEF responds immediately when F is present, => j and t can be ignored. Assume that the Y = AEF is proportional to total F exposure of a person i in a region j. In the simplest framework, the exposure of person i would be F* Θ*Wi+ Di
Conjecture #22
• F is causes increased rates of a very broad set of health conditions associated with immune disorders • More convincing to show in children, since they have not
yet changed counties or had a chance to vary as much by socioeconomics or been exposed to as many other environmental factors
• Infections, allergies, skin problems, stomach problems likely candidates
Ellis 79
Conjecture #23
• Rates of F sensitive acute conditions will increase when people move from counties or MSA without F to counties with F.
– Counties only available from 2007 to 2010 in MarketScan
– Could look at other panel data
– Stronger effect in acute than chronic conditions
– Delayed impact on chronic conditions
Ellis 80
Conjecture #24, 25
• Among fluoridated water systems, smaller water systems will have greater variability in F than larger water systems
• Incidence of F related conditions will be greater in smaller F systems since the chance of a spike in F is greater
– Reports on daily fluctuations are routinely collected but not reported publicly in the US.
Ellis 81
Ellis 82
State of Ca l i fornia -- Health and Human Services Agency Cal i fornia Department of Publ ic Health
Drinking Water Program
MONTHLY FLUORIDATION OPERATIONS REPORT
DISTRIBUTION SYSTEM MONITORING
System Number:
Telephone No:
Month/Year:
1 Monitoring Location (check one):
2 Distribution System Monitoring (per monitoring plan)
3 Entry Point monitoring (must have a single fluoridation system)
4 (Section 64433.3(a),T22,CCR)
5
6 Testing and Monitoring
7 Instrument (Make/model)
8 Analytical test method
9 Instrument Calibration
10 Date
11
12
13
14
15
16
17 Optimal Fluoride Level (mg/L) (c)
18 Fluoride Control Range (mg/L) (c) Low
19 Fluoride Control Range (mg/L) (c) High
20
21
22
23 Split Fluoride sample collection date
24 Split Fluoride sample laboratory result (mg/L)
25 [Add any additional lab results to right of field result, if needed]
26 (Section 64433.3(c),T22,CCR)
27
28
29
30
31
Was CDPH notified of second fluoride sample
level below the control range? (Y/N/NA)
(Section 64433.7(e),T22,CCR)
Was CDPH notified of any fluoride sample level
0.1 mg/L above the control range? (Y/N/NA)
(Section 64433.7(e),T22,CCR)
Were more than 20% of fluoride daily sample levels
outside the control range? (Y/N)
(a)…..If more than one sample is collected per day, leave blank, and attach worksheet. (Section 64433.5(c),T22,CCR)
(b)…..Leave blank when not fluoridating
NA…..Not Applicable
Certified Treatment Operator signature Date(Section 64415(b),T22,CCR)
(c)…..Level and range must be determined from annual average maximum air
temperatures of past five years, and submit temperature value to the CDPH annually.
(Section 64433.2,T22,CCR)
Instrument ID
Day Date
Fluoride Field
Sample Result
(mg/L) (a)(b)
Sample Site ID / Location (a)
System Name:
Contact Person:
Count-Total
Count outside range
Max
Minimum
(one sample per day)
Ave
In addition, we request that you email this form to CDPH Headquarters at: [email protected] Rev 7/11
Outside range %
Count below control range
Count 0.1 mg/L above control range
To be received by CDPH District Office by 10th day of following month
California daily reporting form Data is collected on daily rates
Conjecture #26, 27
• Fluoride is responsible for higher rates of skin diseases, infections, endocrine disorders, blood forming diseases, musculoskeletal, genitourinary in the US, which are more than twice as prevalent at in the OECD countries.
• Such rates in low F regions should be more similar to OECD countries, and OECD country rates in high F areas should look more like the US.
Ellis 83
Time trends point to distinct diseases related to Fluoride: Ratio of US to OECD average diseases
Source: JAMA November 13, 2013 “The Anatomy of Health Care in the United States” Hamilton Moses III, MD1,2; David H. M. Matheson, MBA, JD4; E. Ray Dorsey, MD, MBA2,5; Benjamin P. George, MPH3; David Sadoff, BA4;
Satoshi Yoshimura, PhD4
Ellis 84
Ellis
http://www.cdc.gov/fluoridation/safety/dental_fluorosis.htm
85
Normal
Questionable
Very mild
Mild
Moderate
Severe
What does dental fluorosis look like?
• Very mild and mild forms of dental fluorosis—teeth have scattered white flecks,
occasional white spots, frosty edges, or fine, lacy chalk-like lines. These changes
are barely noticeable and difficult to see except by a dental health care
professional.
• Moderate and severe forms of dental fluorosis—teeth have larger white spots
and, in the rare, severe form, rough, pitted surfaces.
Ellis 86
"Very Mild"/Mild Fluorosis
Photo by Hardy Limeback, DDS
"Very Mild" Fluorosis
Source of Photo Unknown
Mild Fluorosis
Photo by Hardy Limeback, DDS
Moderate Fluorosis
13.6
22.2
29.9
33.8
29.4
44.9
1930-40 H Trendley Dean
1978-82 US Public Health Service
1986-87 NIDR
1999-00 NHANES, Age 16-19
2001-02 NHANES, Age 16-19
2003-04 NHANES, Age 16-19
Figure 1. Prevalence of dental fluorosis in various studies over time
Concerning increase in rates of dental fluorosis, a symptom of excess fluoride
Ellis 87
Conjecture #28, 29
• Since dental fluorosis is a strong indicator of excess fluoride in the drinking water, the county average rate of fluorosis should be strong predictor of rates of numerous chronic diseases. – Could use NHANES data which is available across
many years, and sporadically has asked about fluorosis.
– Could look for correlations with F and with other disorders associated with F.
Ellis 88
Conjecture #30
• College students could self report whether they have fluorosis and where they spent their childhood growing up. – One could do a survey of college students asking for
only two pieces of information after viewing these images.
– When you look in a mirror, do you have any white spots on your teeth?
– What town in the US did you spend the majority of your years from age 0 to ten?
– Need IRB review of survey before starting.
Ellis 89
Conjecture #31-34
• School performance will be poorer in areas with high rates of dental fluorosis.
• Incomes will be lower in areas with high rates of dental fluorosis.
• Individuals with dental fluorosis will have lower income and lower rates of high school and college graduation
• Individuals with dental fluorosis will have lower income than individual without fluorosis
Ellis 90
Key Literature
Books National Research Council, 2006 “Fluoride in Drinking Water: A Scientific Review of EPA's Standards” Freeze and Lehr (2009) The Fluoride Wars: How a Modest Public Health Measure Became America's Longest Running Political Melodrama Connett, Beck, and Micklem (2010) The Case Against Fluoride: How Hazardous Waste Ended Up in Our Drinking Water and the Bad Science and Powerful Politics That Keep It There
Articles Glied and Neidel (2010) JHR The Economic Value of Teeth ”Changing from a non-fluoridated to fluoridated community results in roughly one-third of a tooth more
in adulthood, and these results are highly insensitive to numerous county level controls, supporting the exogeneity of CWF.”
“…access to water fluoridation during childhood increases earnings by roughly 2% overall, with a larger effect for women.”
“All results are remarkably robust to alternative specifications, including controls for various trends and numerous community level variables.”
Neidell, Herzog, and Glied, (2010). AJPH "The Association Between Community Water Fluoridation and Adult Tooth Loss" “Methods. Data from the 1995 through 1999 BRFSS merged with data from the 1992 Water Fluoridation Census, indicate that CWF levels in the county of residence at the time of the respondent's birth are significantly related to tooth loss but current CWF levels are not.
Ho and Neidell (2009) NBER WP Equilibrium effects of public goods: The impact of community water fluoridation on dentists
91 Ellis
Three types of studies already done at BU 2012-2014
• Analysis of 2007 MarketScan privately insured inpatient and outpatient claims on 45 million people using 1991 F levels, with all analysis of 2424 counties. Annual levels
• Analysis of 2007 Medicare Part A and B claims on 1.4 million elderly using 1991 F levels in 2424 counties. Annual levels
• Analysis of 2007-2010 claims from Alabama, in 67counties. Monthly rates.
Ellis 92
Preview of Alabama monthly Results
• Difficult to distinguish short run effects of fluctuations of fluoride from what would be expected by statistical chance (using only one state).
• Some evidence of significant increases in payments for fluoride related acute conditions, with offsetting reductions in spending on all other conditions
• Appears to be that a four month moving average of effects works best.
93 Ellis
MarketScan data Analysis of Alabama Monthly patterns
• Used Thomson Reuters Marketscan Commercial Claims and Encounter data for 2007-2010.
• Extracted all of the claims for 1,918,294 people with Alabama county codes for at least one month
• Summarized for each person at the year-month level: – 46,335,432 inpatient and outpatient claims
– 19,687,152 pharmacy claims
• Final sample contains 19 million person-months of observations with up to 48 months of information on each person, spread among 67 Alabama counties
94 Ellis
Current project uses three different datasets
• Water fluoridation levels from the CDC’s My Water’s Fluoride
• Insurance claims data from Thomson Reuter’s Marketscan Commercial Claims and Encounter data, 2007-2010 on 45 million privately insured people
• Area Resource File (ARF) data for county control variables (cross sectional models)
95 Ellis
Marketscan summaries used:
• For each person in each eligible month, identifying each of 394 distinct condition categories (CCs) in which there is at least one diagnosis
• Diagnoses organized by Verisk/DxCG classification system, related to the same system used by the US Medicare program (Condition Categories)
• Counts of diagnoses, claims, emergency department visits, admissions, and payments.
• The frequency of fluoride-related diagnoses and sum of payments on fluoride-related claims.
Ellis 96
CDC provides water fluoridation data on its web site My Water’s Fluoride
• Data by water system
• Monthly and annual tables
• Erratic quality
• 13 states not participating, but statistics on all states actually available on the CDC web site.
Ellis 97
98 Ellis
1992
County-Level Control Variables from the ARF
Var Description Sample Mean Std. Dev.
arf01 Average active MDs per capita in 2006 2424 0.00143 0.00145
arf02 Average number of hospitals per capita in 2005 2424 0.00007 0.00009
arf03 Average hospital admissions per capita in 2005 2424 0.107 0.078
arf04 Average inpatient days per capita in 2005 2424 0.959 1.384
arf05 Average medical expenditure per capita in 2005 (1000's) 2424 2.201 1.872
arf06 Average income per capita in 2005 2424 28032 6668
arf07 Percentage of population over 65 in 2006 2424 14.8 4.0
arf08 Percentage of persons in poverty in 2005 2424 14.4 5.9
arf09 percent of persons 25+ with less than 9 years schooling in 2000 2424 8.68 5.01
arf10 percent of persons 25+ with more than 4 years college in 2000 2424 17.19 7.84
arf11 percent urban population in 2000 2424 46.32 29.00
AGESEX 32 dummies for share of sample in various age and sex intervals 99 Ellis
100 Ellis
101 Ellis
Fluoride Toxicity Clinical Presentation
Gastrointestinal signs • Hypersalivation • Nausea • Vomiting • Diarrhea • Abdominal pain • Dysphagia • Mucosal injury
Electrolyte abnormalities • Hypocalcemia • Hypomagnesemia • Hyperkalemia • Hypoglycemia
Neurologic effects • Headache • Tremors • Muscular spasm • Tetanic contractions • Hyperactive reflexes • Seizures • Muscle weakness
Cardiovascular • Widening of QRS waves in ECG • Various arrhythmias • Shock • Cardiac arrest
Downloaded from http://emedicine.medscape.com/article/814774-clinical#a0217 on 3/14/2012 102 Ellis
Chronic and Acute Conditions Associated with Fluoride Each number is a cite (not all peer reviewed)
Abnormal Sweating (18) Birth Defects (5) Decrease in Testosterone (32)
Eczema (2) Glaucoma (174) Inflammatory Bowel Disease
Acne (2,3) Blind Spots (3) Delayed Eruption of Teeth (28)
Edema(3) Goitre (2) Inner Ear Disorders (2,5)
ADHD/Learning Disorders (4,7)
Body temperature disturbances (13)
Dementia (2) Eosinophilia (15) Growth Disturbances (1) Irritability (18)
Allergies (2) Breast Cancer (5) Demyelinizing Diseases (2, 35)
Epilepsy (2) Headache (2) Joint Pains (8)
Alopecia (Hair-loss)(18) Cachexia (wasting away)(2)
Dental Abnormalities (2) Excessive Sleepiness (8) Hearing Loss (5) Kidney Failure (2)
Alzheimer’s Disease (5,6,46)
Carpal Tunnel Syndrome (5)
Dental Arch smaller (27) Eye, ear and nose disorders (8)
Heart Disorders Lack of Co-ordination (2)
Anaphylactic Shock (2) Cataracts (2) Dental enamel more porous (29)
Fatigue (2,13) Heart Failure (3) Lack of Energy (8)
Anemia (15) Change in blood pressure(=/-) (2)
Dentral Crowding (23) Fearfulness (1,18) Heart Palpitations (13) Loss of Appetite (2)
Aorta Calcification (2) Chest pain (26) Dentral Fluorosis (Mottling of teeth)
Fever (13) Hemorrhage (1,2) Loss of Consciousness (2)
Apnea (Cessation of breath)
Cholelithiasis (Gallstones)(2)
Depression (8) Fibromyalgia (2) Hepatitis (2) Loss of IQ (25)
Arthralgia (2) Chronic Fatigue Syndrome (2)
Diabetes Insipidus (36a,b)
Fibrosarcoma (3) Hives (3) Loss of Spermatogenesis (33)
Arthritis (8, 13) Cold Shivers (13) Diabetes Mellitus (2) Fibrosis (3) Hoarseness (18) Low Birth Weight (5) Asthenia (Weakness) (18)
Collagen breakdown (3) Diarrhea (8) Fingernails:Brittle (1,3) Hyperparathyroidism (2) Lung Cancer (3)
Asthma (2) Coma (1,3) Dizziness (8,13) Fingernails:Lines/Grooves (1)
Hypertension (8) Lupus (3)
Ataxia (2) Concentration Inability (13,8)
Down Syndrome (10) Forgetfulness (3) Hypoplasia (40) Magnesium Deficiency (2)
Atherosclerosis (3) Constipation (52) Dry Mouth (2) Gastric Ulcers (2) Immunosuppression (3) Memory Loss (13)
Autism (169) Convulsions (2) Dyspepsia (8) Gastro-disturbances (8) Impotence (3) Mental Confusion (20)
Back Pain (2) Crying easily for no apparent reason (18)
Dystrophy (3) Giant Cell Formation Incoherence (8) Migraine (8)
Behavioural Problems (3) Death (3) Early/Delayed Onset of Puberty(14)
Gingivitis (19, 173) Infertility (2,3) Monisiliasis (Candidasis) (162)
103 Ellis
More fluorosis/high altitudes (30,31)
Polyneuropathy (2) Skeletal Changes (2) Uterine Bleeding (2)
Mouth Sores (2) Polyurea (2) Skin Irritations (13,8) Uterine Cancer (23)
Multiple Sclerosis (4) Premature Delivery (16) Skin Pigmentation (2) Vaginal Bleeding (5)
Muscle Cramps (3) Pruritis (Itchy Skin) (3) Sleep Disorders (2) Vas Deferens Alterations (5)
Muscle Stiffness (3) Pulminary Edema (2) Slipped Epiphysis Vertigo (8)
Muscle Weakness (2) Pyelocystitis (2) Sluggishness (2) Visual disturbances (13,8)
Muscoskeletal Disease (3) Recurring Colds (18) Spondylitis, ankylosing (5) Vitiligo (white spots/skin) (2)
Myalgia (Muscle Pain) (2) Respiratory Complications (13,8)
Stillbirths (2) Weak Pulse (13)
Myotrophy (Muscle wasting) (2)
Restlessness (13) Swallowing Difficulties (Dysphagia) (13)
Weight Disturbances (2)
Nausea (8,13) Retinitis (2) Swelling in Face (Angioedema) (3)
Zinc Deficiency (2)
Optic Neuritis (2) Rhinitis (38) Telangiectasia (166)
Oral Squamous Cell Carcinoma (22)
Sceroderma (3) Testicular Growth/Alteration (2, 42)
Osteoarthritis (2) Schizophrenia (18) Thirst (13)
Osteoporosis (2) Secondary teeth erupt later (16)
Thrombosis (39)
Osteosarcoma (22b) Seizures (13) Thyroid Cancer (22)
Otosclerosis Sensitive to light (1,17) Tingling Sensations(18)
Parkinson’s Disease (5) Shortness of Breath (13) Tinnitus (8)
Pins & Needles (18) SIDS (16) Ulcerative Colitis (41) Polydipsia (2) Sinus Infections (2,8) Urticaria (2)
http://poisonfluoride.com/pfpc/html/symptoms.html 104 Ellis
Finding associated diagnoses
• With help from BU RA Karim Nagib, I hired remote coders to look up the ICD-9 diagnoses for each of these conditions.
• 2282 out of 15,000 diagnoses were on this list
• 1062 are considered acute conditions related to fluoride
• Full list, and chronic list were used to sum: – Number of acute and all F-related diagnoses
– Sums of payments in month with at least one F-related diagnosis
Ellis 105
Acute Conditions Associated with Fluoride
Ellis 106
Tired
anemia
atherosclerosis
chronic fatigue syndrome
excessive sleepiness
fatigue
fibromyalgia
headache
migraine
muscle cramps
restlessness shortness of breath
sleep disorders
weak pulse
Lazy behavioural problems dizziness lack of co- ordination lack of energy sluggishness
Sore allergies arthritis asthma back pain carpal tunnel syndrome chest pain
collagen breakdown constipation convulsions diarrhea dry mouth dystrophy edema fearfulness fever gastric ulcers
gastro-disturbances gingivitis thirst tinnitus
ulcerative colitis
Sore.2 hoarseness
inflammatory bowel disease
inner ear disorders
joint pains
lupus
muscle stiffness
muscle weakness
myalgia
myotrophy
nausea pruritis
pyelocystitis
rhinitis
scleroderma
sensitive to light
sinus infections
spondylitis
swallowing difficulties
Sad crying easily for no apparent reason
depression
impotence
irritability
loss of appetite
loss of consciousness
Forgetful
concentration inability incoherence memory loss mental confusion
Ugly
acne
alopecia
eczema
fingernails:brittle
fingernails:lines/grooves
hives
mouth sores
retinitis
skin irritations
skin pigmentation
swelling in face
telangiectasia
urticaria (hives)
Monthly Effects of Fluoride in AL (Alabama) Using four different lagged levels of monthly average CDC F,
(imputing missing with natural levels) F No Lag F-1 F-2 F-3
Utilization measures Mean Coef T-ratio Coef T-ratio Coef T-ratio Coef T-ratio
# of claims 2.447 0.044 1.03 0.040 0.88 0.055 1.17 0.095 ** 2.15
# of diagnoses 3.110 0.082 1.11 0.083 1.08 0.134 * 1.73 0.198 *** 2.68
ER visits 0.026 -0.001 -1.51 -0.001 -1.35 -0.001 -0.55 0.000 -0.04
Admissions 0.012 0.000 -0.22 0.000 -0.06 0.000 0.29 0.001 1.19
total payments 7.049 -0.447 -0.48 -0.678 -1.10 -0.481 -0.93 -0.397 -0.87
Subsets of # of diags
F-related diags 1.062 0.008 0.23 0.009 0.24 0.030 0.82 0.058 * 1.71
Non-F-related diags 2.049 0.074 1.49 0.074 1.45 0.104 ** 2.10 0.140 *** 2.80
Acute F-related diags 0.828 0.010 0.36 0.010 0.32 0.032 1.05 0.025 0.86
Non-acute F-related diags 2.283 0.071 1.31 0.073 1.29 0.102 * 1.84 0.173 *** 2.97
Subsets of total payments
F-related $ 106.49 -5.17 -0.61 -2.65 -0.32 3.03 0.37 10.32 1.36
Non-F-related $ 260.27 -19.33 -1.30 -16.80 -1.15 -17.00 -1.22 15.77 1.14
Acute F-related $ 75.04 5.15 0.96 7.36 1.48 7.08 1.36 7.06 1.52
Non-acute F-related $ 291.72 -29.66 * -1.68 -26.81 -1.54 -21.05 -1.25 19.04 1.16
Observations 3216 3149 3082 3015
107 Ellis
Monthly Effects of Fluoride in AL Using four month moving average of county CDC F,
(imputing missing with natural levels) F_MA(4)
Utilization measures Mean Coef T-ratio R-square Treatment effect # of claims 2.447 0.119 1.63 0.723 5% # of diagnoses 3.110 0.248 ** 2.14 0.734 8% ** ER visits 0.026 0.000 -0.29 0.649 -2% Admissions 0.012 0.001 0.51 0.196 6% total payments 7.049 -0.657 -0.81 0.090 -9% Subsets of # of diags F-related diags 1.062 0.065 1.22 0.688 6% Non-F-related diags 2.049 0.184 ** 2.32 0.693 9% ** Acute F-related diags 0.828 0.046 1.00 0.731 6% Non-acute F-related diags 2.283 0.202 ** 2.33 0.677 9% ** Subsets of total payments F-related $ 106.49 11.33 1.24 0.217 11% Non-F-related $ 260.27 -11.86 -0.56 0.199 -5% Acute F-related $ 75.04 15.82 ** 2.35 0.211 21% ** Non-acute F-related $ 291.72 -16.35 -0.69 0.201 -6%
Observations 3015
108 Ellis
AL results: Time series regressions using four month moving average F to predict 394 CCs
showing Cs with N>500 cases per month, and t>1.96
Ellis 109
CC
Monthl
y Cases Mean Coef
T-
ratio CC Label
Treatment
effect
CC295 547 0.0011 0.00079 *** 3.74 Chronic Kidney Disease Up To Stage IV and Unspecified 72% ***
CC250 561 0.0011 0.00074 *** 3.40 Arteriosclerosis / Aneurism / Other Vascular Disease 66% ***
CC138 691 0.0014 0.00087 *** 3.89
Anemia in Chronic Illness / Other Blood and Blood Forming
Organ Disease 63% ***
CC110 938 0.0019 0.00071 *** 2.68 Bone Cysts and Other and Unspecified Bone/Cartilage Disorders 38% ***
CC133 651 0.0013 0.00041 ** 2.06 Upper Extremity Soft Tissue Disorders 31% **
CC115 1050 0.0021 0.00062 ** 2.03 Other Musculoskeletal and Connective Tissue Disorders 30% **
CC044 8910 0.0178 0.00259 *** 3.24 Diabetes with No or Unspecified Complications 15% ***
CC388 9080 0.0182 0.00202 ** 2.04 Other Postsurgical States / Elective Surgery / Aftercare 11% **
CC234 17790 0.0356 0.00367 *** 2.73 Hypertension 10% ***
CC323 2200 0.0044 -0.00108 *** -2.84 Uncompleted Pregnancy With No or Minor Complications -25% ***
CC296 1202 0.0024 -0.00069 ** -2.24 Urinary Calculi / Stricture / Reflux / Retention -29% **
CC039 1992 0.0040 -0.00124 *** -3.48 Other Benign, Uncertain, and In Situ Neoplasms -31% ***
CC093 925 0.0018 -0.00076 *** -2.75
Pathologic Dislocations and Miscellaneous Pelvic Joint
Disorders -41% ***
CC381 685 0.0014 -0.00070 *** -3.05 Rehabilitation -51% ***
CC252 600 0.0012 -0.00073 *** -2.58 Superficial Thrombophlebitis / Varicosity -61% ***
CC387 528 0.0011 -0.00073 *** -3.60
Non-Joint-Replacement Orthopedic Aftercare and Arthrodesis
Status -69% ***
CC CC Label T-ratio
Treatment
effect T-ratio
Treatment
effect
Annual
rate per
10,000
ACC001 Infectious and Parasitic 0.59 4% 6 11% *** 790
ACC002 Malignant Neoplasm 0.69 5% -1.05 -4% 150
ACC003 Benign/In Situ/Uncertain Neoplasm -1.83 -10% * 1.41 3% 735
ACC004 Diabetes 3.30 14% *** 3.71 12% *** 439
ACC005 Nutritional and Metabolic 0.69 3% 4.44 8% *** 1335
ACC006 Liver 1.51 18% 0.36 1% 101
ACC007 Gastrointestinal -1.10 -5% 4.9 9% *** 1084
ACC008 Musculoskeletal and Connective Tissue -1.59 -4% 4.99 6% *** 2463
ACC009 Hematological 0.09 1% 1.61 5% 220
ACC011 Substance Abuse -0.74 -10% 3.03 14% *** 122
ACC012 Mental -1.30 -7% 1.48 4% 598
ACC013 Developmental Disability -0.97 -11% 3.42 13% *** 114
ACC014 Neurological 0.80 4% 4.29 8% *** 582
ACC016 Heart 2.41 8% ** 5.09 9% *** 1279
ACC018 Vascular 0.88 11% 4.88 17% *** 159
ACC019 Lung -0.81 -5% 4.44 8% *** 969
ACC020 Eyes -0.46 -2% 2.75 7% *** 823
ACC021 Ears, Nose, and Throat 1.44 4% 7.17 10% *** 2680
ACC022 Urinary System -0.24 -1% 4.15 8% *** 547
ACC023 Genital System -1.51 -7% 2.63 6% *** 786
ACC024 Pregnancy-Related -3.00 -23% *** 2 6% ** 178
ACC025 Skin and Subcutaneous 0.81 4% 2.5 4% ** 1237
ACC026 Injury, Poisoning 0.33 2% 1.46 3% 791
ACC027 Symptoms, Signs and Ill-Defined Conditions 1.15 3% 7.88 10% *** 2671
ACC030 Screening/History -0.42 -1% 3.69 4% *** 3640
CC009 Other Non-Chronic Infectious Diseases 0.32 2% 6.1 11% *** 738
CC036 Benign and Uncertain Digestive and Urinary Neoplasms 0.23 3% 1.13 6% 128
CC038 Benign Neoplasms of Skin, Breast, Eye -0.99 -8% 1.69 4% * 338
CC039 Other Benign, Uncertain, and In Situ Neoplasms -3.48 -31% *** -2.24 -7% ** 182
CC044 Diabetes with No or Unspecified Complications 3.24 15% *** 3.68 14% *** 367
CC049 Hyperlipidemia 1.87 9% * 3.86 9% *** 881
CC052 Thyroid/Testicular/Ovarian and Metabolic/Nutritional Disorders-1.16 -7% 1.7 6% * 361
CC055 Disorders of Fluid/Electrolyte/Acid-Base Balance -0.80 -11% 4.4 21% *** 109
CC076 Other Chronic Gastrointestinal Disorders -0.57 -4% 3.2 8% *** 359
CC077 Other Gastrointestinal Disorders -0.99 -5% 3.5 9% *** 546
CC098 Intervertebral Disc Disorders, Spondylosis and Allied Disorders - Lower Back/NOS0.79 5% 3.1 12% *** 150
CC102 Nonspecific and Other Backaches/Pains/Disorders - Upper Back and Neck-1.18 -7% 3.06 15% *** 270
CC104 Nonspecific and Other Backaches/Pains/Disorders - Lower Back and NOS-1.05 -5% 2.73 11% *** 442
CC111 Osteoarthritis, Except of Spine, Hip, or Knee -0.21 -2% 1.12 5% 121
CC114 Other and NOS Soft Tissue Disorders -1.18 -6% 0.33 1% 238
CC125 Pathologic Dislocations and Miscellaneous Joint Disorders of Leg or Multiple Joints0.20 1% 3.64 9% *** 310
CC131 Shoulder Joint and Soft Tissue Disorders -0.19 -2% 3 3 10% *** 167
CC134 Injuries and Joint Disorders of Forearm and Hand 0.37 3% 2.2 5% ** 293
CC141 Nutritional Deficiency and Other/Unspecified Anemias and Blood and Spleen Disease-0.95 -8% 1.17 5% 129
CC159 Other Psychiatric Disorders -1.07 -11% 1.27 4% 184
CC168 Major Depression -1.30 -14% 0.15 1% 104
CC170 Depression 0.60 9% 0.28 1% 174
CC202 Mononeuropathy, Other Neurological Conditions/Injuries -0.12 -1% -0.12 -1% 138
CC203 Migraine and Tension Headache 0.83 8% 3.5 12% *** 150
CC204 Other Headache -0.05 0% 5.03 15% *** 190
CC219 Coronary Atherosclerosis/Other Chronic Ischemic Heart Disease4.07 44% 0.76 4% 127
CC234 Hypertension 2.73 10% *** 4.46 10% *** 825
CC257 Viral and Unspecified Pneumonia, Pleurisy 1.83 25% * 2.2 9% ** 104
CC265 Other Lung Disorders -0.31 -3% 4.93 12% *** 542
CC267 Asthma -0.30 -3% -1.28 -4% 217
CC277 Cataract -1.64 -22% -0.07 0% 104
CC278 Other Chronic Eye Disorders 0.47 6% 1.76 8% * 104
CC279 Glaucoma 0.55 6% -0.2 -1% 116
CC280 Other Non-Chronic Eye Disorders -0.20 -1% 2.33 7% ** 405
CC284 Other Chronic Ear, Nose, Throat, and Mouth Disorders 0.62 3% 4.37 10% *** 717
CC285 Other Non-Chronic Ear, Nose, Throat, and Mouth Disorders 1.62 6% 6.32 10% *** 1882
CC296 Urinary Calculi / Stricture / Reflux / Retention -2.24 -29% ** 2.57 10% ** 101
CC300 Other Urinary Tract Disorders 0.91 12% 2.83 14% *** 101
CC305 Acute and Other Urinary Tract Infection -1.06 -7% 0.83 2% 307
CC309 Perimenopausal and Other Congenital and Acquired Female Genital Disorders-1.10 -7% 3.19 9% *** 304
CC310 Vaginal/Cervical Diseases / Other Female Genital Disorders -1.04 -8% 0.55 2% 174
CC329 Cellulitis, Local Skin Infection -1.59 -12% 0.01 0% 232
CC330 Other Chronic Dermatological Disorders -0.69 -9% 1.19 4% 120
CC331 Other Dermatological Disorders 1.57 8% 2.73 5% *** 870
CC340 Other Injuries -0.51 -3% 1.31 3% 365
CC342 Poisonings and Allergic Reactions 1.36 21% -2.46 -11% ** 120
CC346 Persistent Sleep Disorders / Other Chronic Problems 1.46 12% 4.13 18% *** 114
CC347 Other Major Symptoms, Abnormalities -0.51 -2% 5.89 10% *** 1120
CC348 Dyspnea, Distress, Other Respiratory/Chest Symptoms 0.53 4% 4.17 12% *** 225
CC349 Minor Symptoms, Signs, Findings 0.97 3% 5.12 9% *** 1332
CC381 Rehabilitation -3.05 -51% *** 4.07 29% *** 124
CC383 Screening/Observation/Special Exams -0.58 -2% 2.15 3% ** 3332
CC384 History of Disease 0.37 4% 4.91 17% *** 269
CC388 Other Postsurgical States / Elective Surgery / Aftercare 2.04 11% ** 6.9 28% *** 348
Comparison of monthly time series (AL, 2007-10) and cross sectional results (National, 2424 counties, 2006)
Ellis 110
CC CC Label T-ratio
Treatment
effect T-ratio
Treatment
effect
Annual
rate per
10,000
ACC001 Infectious and Parasitic 0.59 4% 6 11% *** 790
ACC002 Malignant Neoplasm 0.69 5% -1.05 -4% 150
ACC003 Benign/In Situ/Uncertain Neoplasm -1.83 -10% * 1.41 3% 735
ACC004 Diabetes 3.30 14% *** 3.71 12% *** 439
ACC005 Nutritional and Metabolic 0.69 3% 4.44 8% *** 1335
ACC006 Liver 1.51 18% 0.36 1% 101
ACC007 Gastrointestinal -1.10 -5% 4.9 9% *** 1084
ACC008 Musculoskeletal and Connective Tissue -1.59 -4% 4.99 6% *** 2463
ACC009 Hematological 0.09 1% 1.61 5% 220
ACC011 Substance Abuse -0.74 -10% 3.03 14% *** 122
ACC012 Mental -1.30 -7% 1.48 4% 598
ACC013 Developmental Disability -0.97 -11% 3.42 13% *** 114
ACC014 Neurological 0.80 4% 4.29 8% *** 582
ACC016 Heart 2.41 8% ** 5.09 9% *** 1279
ACC018 Vascular 0.88 11% 4.88 17% *** 159
ACC019 Lung -0.81 -5% 4.44 8% *** 969
ACC020 Eyes -0.46 -2% 2.75 7% *** 823
ACC021 Ears, Nose, and Throat 1.44 4% 7.17 10% *** 2680
ACC022 Urinary System -0.24 -1% 4.15 8% *** 547
ACC023 Genital System -1.51 -7% 2.63 6% *** 786
ACC024 Pregnancy-Related -3.00 -23% *** 2 6% ** 178
ACC025 Skin and Subcutaneous 0.81 4% 2.5 4% ** 1237
ACC026 Injury, Poisoning 0.33 2% 1.46 3% 791
ACC027 Symptoms, Signs and Ill-Defined Conditions 1.15 3% 7.88 10% *** 2671
ACC030 Screening/History -0.42 -1% 3.69 4% *** 3640
CC009 Other Non-Chronic Infectious Diseases 0.32 2% 6.1 11% *** 738
CC036 Benign and Uncertain Digestive and Urinary Neoplasms 0.23 3% 1.13 6% 128
CC038 Benign Neoplasms of Skin, Breast, Eye -0.99 -8% 1.69 4% * 338
CC039 Other Benign, Uncertain, and In Situ Neoplasms -3.48 -31% *** -2.24 -7% ** 182
CC044 Diabetes with No or Unspecified Complications 3.24 15% *** 3.68 14% *** 367
CC049 Hyperlipidemia 1.87 9% * 3.86 9% *** 881
CC052 Thyroid/Testicular/Ovarian and Metabolic/Nutritional Disorders-1.16 -7% 1.7 6% * 361
CC055 Disorders of Fluid/Electrolyte/Acid-Base Balance -0.80 -11% 4.4 21% *** 109
CC076 Other Chronic Gastrointestinal Disorders -0.57 -4% 3.2 8% *** 359
CC077 Other Gastrointestinal Disorders -0.99 -5% 3.5 9% *** 546
CC098 Intervertebral Disc Disorders, Spondylosis and Allied Disorders - Lower Back/NOS0.79 5% 3.1 12% *** 150
CC102 Nonspecific and Other Backaches/Pains/Disorders - Upper Back and Neck-1.18 -7% 3.06 15% *** 270
CC104 Nonspecific and Other Backaches/Pains/Disorders - Lower Back and NOS-1.05 -5% 2.73 11% *** 442
CC111 Osteoarthritis, Except of Spine, Hip, or Knee -0.21 -2% 1.12 5% 121
CC114 Other and NOS Soft Tissue Disorders -1.18 -6% 0.33 1% 238
CC125 Pathologic Dislocations and Miscellaneous Joint Disorders of Leg or Multiple Joints0.20 1% 3.64 9% *** 310
CC131 Shoulder Joint and Soft Tissue Disorders -0.19 -2% 3 3 10% *** 167
CC134 Injuries and Joint Disorders of Forearm and Hand 0.37 3% 2.2 5% ** 293
CC141 Nutritional Deficiency and Other/Unspecified Anemias and Blood and Spleen Disease-0.95 -8% 1.17 5% 129
CC159 Other Psychiatric Disorders -1.07 -11% 1.27 4% 184
CC168 Major Depression -1.30 -14% 0.15 1% 104
CC170 Depression 0.60 9% 0.28 1% 174
CC202 Mononeuropathy, Other Neurological Conditions/Injuries -0.12 -1% -0.12 -1% 138
CC203 Migraine and Tension Headache 0.83 8% 3.5 12% *** 150
CC204 Other Headache -0.05 0% 5.03 15% *** 190
CC219 Coronary Atherosclerosis/Other Chronic Ischemic Heart Disease4.07 44% 0.76 4% 127
CC234 Hypertension 2.73 10% *** 4.46 10% *** 825
CC257 Viral and Unspecified Pneumonia, Pleurisy 1.83 25% * 2.2 9% ** 104
CC265 Other Lung Disorders -0.31 -3% 4.93 12% *** 542
CC267 Asthma -0.30 -3% -1.28 -4% 217
CC277 Cataract -1.64 -22% -0.07 0% 104
CC278 Other Chronic Eye Disorders 0.47 6% 1.76 8% * 104
CC279 Glaucoma 0.55 6% -0.2 -1% 116
CC280 Other Non-Chronic Eye Disorders -0.20 -1% 2.33 7% ** 405
CC284 Other Chronic Ear, Nose, Throat, and Mouth Disorders 0.62 3% 4.37 10% *** 717
CC285 Other Non-Chronic Ear, Nose, Throat, and Mouth Disorders 1.62 6% 6.32 10% *** 1882
CC296 Urinary Calculi / Stricture / Reflux / Retention -2.24 -29% ** 2.57 10% ** 101
CC300 Other Urinary Tract Disorders 0.91 12% 2.83 14% *** 101
CC305 Acute and Other Urinary Tract Infection -1.06 -7% 0.83 2% 307
CC309 Perimenopausal and Other Congenital and Acquired Female Genital Disorders-1.10 -7% 3.19 9% *** 304
CC310 Vaginal/Cervical Diseases / Other Female Genital Disorders -1.04 -8% 0.55 2% 174
CC329 Cellulitis, Local Skin Infection -1.59 -12% 0.01 0% 232
CC330 Other Chronic Dermatological Disorders -0.69 -9% 1.19 4% 120
CC331 Other Dermatological Disorders 1.57 8% 2.73 5% *** 870
CC340 Other Injuries -0.51 -3% 1.31 3% 365
CC342 Poisonings and Allergic Reactions 1.36 21% -2.46 -11% ** 120
CC346 Persistent Sleep Disorders / Other Chronic Problems 1.46 12% 4.13 18% *** 114
CC347 Other Major Symptoms, Abnormalities -0.51 -2% 5.89 10% *** 1120
CC348 Dyspnea, Distress, Other Respiratory/Chest Symptoms 0.53 4% 4.17 12% *** 225
CC349 Minor Symptoms, Signs, Findings 0.97 3% 5.12 9% *** 1332
CC381 Rehabilitation -3.05 -51% *** 4.07 29% *** 124
CC383 Screening/Observation/Special Exams -0.58 -2% 2.15 3% ** 3332
CC384 History of Disease 0.37 4% 4.91 17% *** 269
CC388 Other Postsurgical States / Elective Surgery / Aftercare 2.04 11% ** 6.9 28% *** 348
Comparison of monthly time series (AL, 2007-10) and cross sectional results (National, 2424 counties, 2006)
CC CC Label T-ratio
Treatment
effect T-ratio
Treatment
effect
Annual
rate per
10,000
ACC001 Infectious and Parasitic 0.59 4% 6 11% *** 790
ACC002 Malignant Neoplasm 0.69 5% -1.05 -4% 150
ACC003 Benign/In Situ/Uncertain Neoplasm -1.83 -10% * 1.41 3% 735
ACC004 Diabetes 3.30 14% *** 3.71 12% *** 439
ACC005 Nutritional and Metabolic 0.69 3% 4.44 8% *** 1335
ACC006 Liver 1.51 18% 0.36 1% 101
ACC007 Gastrointestinal -1.10 -5% 4.9 9% *** 1084
ACC008 Musculoskeletal and Connective Tissue -1.59 -4% 4.99 6% *** 2463
ACC009 Hematological 0.09 1% 1.61 5% 220
ACC011 Substance Abuse -0.74 -10% 3.03 14% *** 122
ACC012 Mental -1.30 -7% 1.48 4% 598
ACC013 Developmental Disability -0.97 -11% 3.42 13% *** 114
ACC014 Neurological 0.80 4% 4.29 8% *** 582
ACC016 Heart 2.41 8% ** 5.09 9% *** 1279
ACC018 Vascular 0.88 11% 4.88 17% *** 159
ACC019 Lung -0.81 -5% 4.44 8% *** 969
ACC020 Eyes -0.46 -2% 2.75 7% *** 823
ACC021 Ears, Nose, and Throat 1.44 4% 7.17 10% *** 2680
ACC022 Urinary System -0.24 -1% 4.15 8% *** 547
ACC023 Genital System -1.51 -7% 2.63 6% *** 786
ACC024 Pregnancy-Related -3.00 -23% *** 2 6% ** 178
ACC025 Skin and Subcutaneous 0.81 4% 2.5 4% ** 1237
ACC026 Injury, Poisoning 0.33 2% 1.46 3% 791
ACC027 Symptoms, Signs and Ill-Defined Conditions 1.15 3% 7.88 10% *** 2671
ACC030 Screening/History -0.42 -1% 3.69 4% *** 3640
CC009 Other Non-Chronic Infectious Diseases 0.32 2% 6.1 11% *** 738
CC036 Benign and Uncertain Digestive and Urinary Neoplasms 0.23 3% 1.13 6% 128
CC038 Benign Neoplasms of Skin, Breast, Eye -0.99 -8% 1.69 4% * 338
CC039 Other Benign, Uncertain, and In Situ Neoplasms -3.48 -31% *** -2.24 -7% ** 182
CC044 Diabetes with No or Unspecified Complications 3.24 15% *** 3.68 14% *** 367
CC049 Hyperlipidemia 1.87 9% * 3.86 9% *** 881
CC052 Thyroid/Testicular/Ovarian and Metabolic/Nutritional Disorders-1.16 -7% 1.7 6% * 361
CC055 Disorders of Fluid/Electrolyte/Acid-Base Balance -0.80 -11% 4.4 21% *** 109
CC076 Other Chronic Gastrointestinal Disorders -0.57 -4% 3.2 8% *** 359
CC077 Other Gastrointestinal Disorders -0.99 -5% 3.5 9% *** 546
CC098 Intervertebral Disc Disorders, Spondylosis and Allied Disorders - Lower Back/NOS0.79 5% 3.1 12% *** 150
CC102 Nonspecific and Other Backaches/Pains/Disorders - Upper Back and Neck-1.18 -7% 3.06 15% *** 270
CC104 Nonspecific and Other Backaches/Pains/Disorders - Lower Back and NOS-1.05 -5% 2.73 11% *** 442
CC111 Osteoarthritis, Except of Spine, Hip, or Knee -0.21 -2% 1.12 5% 121
CC114 Other and NOS Soft Tissue Disorders -1.18 -6% 0.33 1% 238
CC125 Pathologic Dislocations and Miscellaneous Joint Disorders of Leg or Multiple Joints0.20 1% 3.64 9% *** 310
CC131 Shoulder Joint and Soft Tissue Disorders -0.19 -2% 3 3 10% *** 167
CC134 Injuries and Joint Disorders of Forearm and Hand 0.37 3% 2.2 5% ** 293
CC141 Nutritional Deficiency and Other/Unspecified Anemias and Blood and Spleen Disease-0.95 -8% 1.17 5% 129
CC159 Other Psychiatric Disorders -1.07 -11% 1.27 4% 184
CC168 Major Depression -1.30 -14% 0.15 1% 104
CC170 Depression 0.60 9% 0.28 1% 174
CC202 Mononeuropathy, Other Neurological Conditions/Injuries -0.12 -1% -0.12 -1% 138
CC203 Migraine and Tension Headache 0.83 8% 3.5 12% *** 150
CC204 Other Headache -0.05 0% 5.03 15% *** 190
CC219 Coronary Atherosclerosis/Other Chronic Ischemic Heart Disease4.07 44% 0.76 4% 127
CC234 Hypertension 2.73 10% *** 4.46 10% *** 825
CC257 Viral and Unspecified Pneumonia, Pleurisy 1.83 25% * 2.2 9% ** 104
CC265 Other Lung Disorders -0.31 -3% 4.93 12% *** 542
CC267 Asthma -0.30 -3% -1.28 -4% 217
CC277 Cataract -1.64 -22% -0.07 0% 104
CC278 Other Chronic Eye Disorders 0.47 6% 1.76 8% * 104
CC279 Glaucoma 0.55 6% -0.2 -1% 116
CC280 Other Non-Chronic Eye Disorders -0.20 -1% 2.33 7% ** 405
CC284 Other Chronic Ear, Nose, Throat, and Mouth Disorders 0.62 3% 4.37 10% *** 717
CC285 Other Non-Chronic Ear, Nose, Throat, and Mouth Disorders 1.62 6% 6.32 10% *** 1882
CC296 Urinary Calculi / Stricture / Reflux / Retention -2.24 -29% ** 2.57 10% ** 101
CC300 Other Urinary Tract Disorders 0.91 12% 2.83 14% *** 101
CC305 Acute and Other Urinary Tract Infection -1.06 -7% 0.83 2% 307
CC309 Perimenopausal and Other Congenital and Acquired Female Genital Disorders-1.10 -7% 3.19 9% *** 304
CC310 Vaginal/Cervical Diseases / Other Female Genital Disorders -1.04 -8% 0.55 2% 174
CC329 Cellulitis, Local Skin Infection -1.59 -12% 0.01 0% 232
CC330 Other Chronic Dermatological Disorders -0.69 -9% 1.19 4% 120
CC331 Other Dermatological Disorders 1.57 8% 2.73 5% *** 870
CC340 Other Injuries -0.51 -3% 1.31 3% 365
CC342 Poisonings and Allergic Reactions 1.36 21% -2.46 -11% ** 120
CC346 Persistent Sleep Disorders / Other Chronic Problems 1.46 12% 4.13 18% *** 114
CC347 Other Major Symptoms, Abnormalities -0.51 -2% 5.89 10% *** 1120
CC348 Dyspnea, Distress, Other Respiratory/Chest Symptoms 0.53 4% 4.17 12% *** 225
CC349 Minor Symptoms, Signs, Findings 0.97 3% 5.12 9% *** 1332
CC381 Rehabilitation -3.05 -51% *** 4.07 29% *** 124
CC383 Screening/Observation/Special Exams -0.58 -2% 2.15 3% ** 3332
CC384 History of Disease 0.37 4% 4.91 17% *** 269
CC388 Other Postsurgical States / Elective Surgery / Aftercare 2.04 11% ** 6.9 28% *** 348
Comparison of monthly time series (AL, 2007-10) and cross sectional results (National, 2424 counties, 2006)
Three hypotheses for why some changes are negative (beneficial)
1. Nothing is really happening; it's all a statistical artifact.
2. There really are offsetting beneficial and negative effects of fluoride.
3. We are seeing the anticipated adverse effects, but they are crowding out some other types of visits. – My conjecture #35 is that it is the last one: People go
in to complain about acute effect.
Ellis 113
TABLE 2. Recommended optimal fluoride levels for community public water supply systems (31,32) =================================================================================================== Annual average of maximum daily Recommended Recommended control range air temperatures (8,9) fluoride (mg/L) 0.1-0.5 ------------------------------- concentrations --------------------------------- F C (mg/L) Below Above ------------------------------------------------------------------------------------------------------------------- 50.0-53.7 10.0-12.0 1.2 1.1 1.7 53.8-58.3 12.1-14.6 1.1 1.0 1.6 58.4-63.8 14.7-17.7 1.0 0.9 1.5 63.9-70.6 17.8-21.4 0.9 0.8 1.4 70.7-79.2 21.5-26.2 0.8 0.7 1.3 79.3-90.5 26.3-32.5 0.7 0.6 1.2 Source: http://www.cdc.gov/mmwr/preview/mmwrhtml/00039178.htm#00001294.htm Downloaded from the CDC web site on April 24, 2016
Standards Shown on the CDC Web Site still suggest levels that have Not Been Changed Since 1953
http://www.cdc.gov/fluoridation/engineering.htm
Galagan DJ. Climate and controlled fluoridation. J Am Dent Assoc
1953;47:159-70.
114 Ellis
2016 CDC web site still shows Fluoride Standards for School Water Supplies Advocate 4.5 Times the Community Water
Supply Average TABLE 5. Recommended optimal fluoride levels for school public water supply systems (31,32) ============================================================================================= Annual average of maximum daily Recommended air temperatures (8,9) fluoride Recommended control range (mg/L) -------------------------------- concentrations -------------------------------- F C (mg/L) 20% Below 20% Above --------------------------------------------------------------------------------------------- 50.0 - 53.7 10.0 - 12.0 5.4 4.3 6.5 53.8 - 58.3 12.1 - 14.6 5.0 4.0 6.0 58.4 - 63.8 14.7 - 17.7 4.5 3.6 5.4 63.9 - 70.6 17.8 - 21.4 4.1 3.3 4.9 70.7 - 79.2 21.5 - 26.2 3.6 2.9 4.3 79.3 - 90.5 26.3 - 32.5 3.2 2.6 3.8 --------------------------------------------------------------------------------------------- + Based on 4.5 times the optimal fluoride level for communities. Source: http://www.cdc.gov/mmwr/preview/mmwrhtml/00039178.htm#00001294.htm Downloaded from the CDC web site on March 6, 2012
115 Ellis
Recommended fluoride overfeed actions for community water systems, United States (31) (Guidelines are from Reeves TG 1986, but as still listed on CDC website in 2016) =========================================================================== Fluoride level Actions Recommended ------------------------------------------------------------------------------------------------------------- up to 2.0 mg/L 1. Leave it on. 2. Determine malfunction and repair. 2.1 mg/L to 4.0 mg/L 1. Leave it on. 2. Determine malfunction and repair. 3. Notify supervisor and report to appropriate agencies. 4.1 mg/L to 10.0 mg/L (0. Leave it on.) 1. Attempt repair. 2. If the problem is not corrected quickly, turn it off. 3. Notify supervisor and report to appropriate agencies. 4. Test water samples at several points in the distribution system. Retest if results are still high. 10.1 mg/L or greater + 1. Turn it off immediately … ------------------------------------------------------------------------------------------------------------- + The state might require public notification to prevent consumption of high levels of fluoridated water. Source:http://www.cdc.gov/mmwr/preview/mmwrhtml/00039178.htm#00001294.htmDownloaded April 24, 2016
116 Ellis
Daily intake (mg/person)
Endemic area Coal type Food
Drinking-
water Air Total
Sichuan Soft coal 8.86 0.10 0.67 9.63
Hubei Anthracite 4.12 0.45 0.55 6.12
Jiangxi Anthracite 2.54 0.50 0.24 3.28
Hunan Anthracite 1.81 0.52 0.31 2.64
Huber Anthracite 1.86 0.42 0.15 2.43
Jiangxi (control) Firewood 1.14 0.24 0.11 1.49
Source: WHO, Table 2.4, Downloaded 4/28/2012 from
http://www.who.int/water_sanitation_health/publications/fluoride_drinking_water_full.pdf
Table 2.4 Daily fluoride intake in different endemic areas of China using
Fluoride is also a problem in other countries
117 Ellis
US Fluoride Time Line
1916 The first evidence of brown mottling of teeth is reported in the US, eventually found to be caused by fluorides in water. 1950 The U.S. Public Health Service officially endorses the fluoridation of public water supplies. 1953 Galadan proposes F levels are .7ppm (parts per million) in hot areas, increasing to 1.2 in colder climate areas, with the rationale being that people do not need to drink as much water in colder areas 1955 Crest Fluoride toothpaste is first marketed 1955 “Fluoridated toothpaste should not be used where the water supply is fluoridated." A later decision stipulated that "children under 6 should not use Crest". Both warnings were abandoned in 1958. 1967 Fluoride pills are generally available for free to children from dentists. 1969 The World Health Organization endorses water system fluoridation 1971 Germany bans water fluoridation 1972 Sweden bans water fluoridation 2011 January, the US DHHS and EPA jointly announce a new recommended level for water fluoridation of .7 ppm.
118 Ellis
• 1945: Fluoride's affinity for magnesium and manganese ions enables it to deplete their availability for vital enzyme functions. (Borei, H., "Inhibition of Cellular Oxidation by Fluoride", Arkiv.Kemi,Mineral,Geol., 20A, No. 8, 1945).
• February 10, 1951 issue of JAMA Medical Literature: Symptoms of chronic fluoride poisoning, include "dental fluorosis. Fluoride also tends to accumulate in bones, leading to hypercalcification and brittleness. Ligaments and tendons also become calcified. Serious symptoms may ensue, such as loss of mobility of joints, easy fractures and pressure on the spinal chord. Other effects include baldness in young men, accompanied by increased fluoride concentrations in hair and nails, anemia and decreased blood clotting power due to the binding of calcium. Dysmenorrhea, alterations in growth and weight, lowered birth rate, high incidence of fractyre, thyroid alterations and liver damage have been observed in regions of endemic fluorosis.“
• 1962 A study in Portugal revealed that fluoride at 1ppm concentration caused a 25% decrease in activitiy of the enzyme succinic dehydrogenase in liver tissue, both in test tubes and in animal experiments. In vivo, fluoride at 1ppm inhibited liver activity by 6.4 percent. In kidneys this enzyme activity was reduced by 47.8 percent by fluoride at 1ppm in drinking water. The authors concluded, "significant enzyme inhibition due to prolonged fluoride administration demonstrates the impairment of an important step in cellular metabolism". (Sullivan, W.D.,S.J., and Von Knobeledorff, A.J., Broteria Serie de Ciencias Naturais, Lisbon, 21, No.1, 1962).
• 1966 Testimony presented by John J. Miller, Ph.D, Chicago, Illinois at fluoridation hearings in San Jose, California on March 11, 1966, included the following statement: "Fluoride acts to tie up magnesium - forming magnesium fluoride - an insoluble compound which thus prevents the essential enzyme from using magnesium. As a result, mental processes are seriously interfered with, and nerve reactions throughout the body depressed ... this sort of toxicity is shown by research to play a role in epileptic seizures and other convulsions." [Ref: Fluoridation and Truth Decay, 1974, p.93]
• 1967 The July 1967 Annals of Allergy reported dermatitis and gastro-intestinal conditions from fluoridated toothpaste; and headaches, fever, and blood in stools from Tri-Vi-Flor given to children.
• 1972 The prestigious journal Science, July 14, 1972, requested doctors "Perform Tests and/or Examinations on People Who Have Shown Sensitivity to Fluorides from Fluoridation", and to send the results to a Fact Finding Committee in Milwaukee, Wisconsin, chaired by Dr.R.J.H. Mick in Laurel Springs, New Jersey. The project consisted of a double-blind study using the provocative sub-lingual testings with varying dilutions of a fluoride solution up to a concentration of 1 ppm. The project, held at the Red Carpet Inn in Milwaukee on August 5 and 6, 1972, was a 'continuing study to determine the immediate side effects of individuals extremely sensitive to fluorides'. A number of individuals developed immediate symptoms of headache, burning in the throat, dizziness, nausea and vomiting to test solutions whose concentration were much less than 1 ppm, whereas the placebo (unfluoridated tap water) elicited no reactions.
119 Ellis
120 Ellis
121 Ellis
122 Ellis
New York City 2011 Drinking Water Michael R. Bloomberg Supply and Quality Report
• (Bold text highlights added.) Water Treatment Drinking water entering New York City’s distribution system is treated with chlorine, fluoride, food grade phosphoric acid and sodium hydroxide. New York City uses chlorine to meet disinfection requirements. Fluoride, added since 1966, helps prevent tooth decay. Phosphoric acid is added to create a protective film on pipes that reduces the release of metals, such as lead, from household plumbing. Sodium hydroxide is added to Catskill/Delaware water to raise the pH and reduce corrosivity, which also helps reduce potential exposure to lead.
Fluoride DEP is one of the many water suppliers in New York State that treats drinking water with a controlled, low level of fluoride for consumer dental health protection. According to the United States Centers for Disease Control and Prevention (CDC), fluoride is very effective in preventing cavities when present in drinking water at an optimal range of 0.7 to 1.2 mg/L. The New York City Health Code requires a fluoride concentration of 1.0 mg/L, and the NYSDOH maximum contaminant level (MCL) for fluoride is 2.2 mg/L. During 2011, fluoride was not continuously supplied due to maintenance to the fluoride feed system and other aqueduct construction activities that required the system to be turned off. Fluoridation on the Catskill and Delaware aqueducts was offline 7% and 20% of the time, respectively. There was an extended period of frequent fluoridation interruptions during a 106-day period, from March 15 to June 28, 2011, due to construction work at Delaware Shaft 19. The New York State Dental Association has indicated that a continuous interruption of fluoridation is not expected to have a significant impact on dental health. Outside of this time period, DEP met the required fluoride levels more than 85% of the time. On January 13, 2011, the United States Department of Health and Human Services requested public comment on its proposal to lower the optimal fluoride target dose to 0.7 mg/L. In response NYSDOH issued guidance to public water supplies indicating that water suppliers in New York State could reduce the optimal fluoride target dose to 0.8 mg/L. Based on these developments the New York City Department of Health and Mental Hygiene authorized DEP to lower the target dose for fluoride to 0.8 mg/L. This dosage change took effect on February 14, 2012.
Ellis 123
Speculative Conjecture #35
New York City’s discontinuation of F for 106 days from March 15 to June 28, 2011, provides a powerful natural experiment to look for improvements in acute fluoride-related health conditions during this period and resumption of such conditions afterwards.
Ellis 124
Speculative Conjecture #36
Fluoride may be causally related to Alzheimer’s Disease (NRC 2006) report p. 234: “Because of the great affinity between fluorine and aluminum, it is possible that the greatest impairments of structure and function come about through the actions of charged and uncharged AlF complexes (AlFx). …In a study of more than 3,500 French men and women above the age of 65 (Jacqmin et al. 1994), a significant decrease in cognitive abilities was found when their drinking water contained calcium, aluminum, and fluorine.”
Ellis 125
Speculative Conjecture #37
Fluoride reduces Human IQ (NRC 2006) report p. 221: “In assessing the potential health effects of fluoride at 2-4 mg/L, the committee found three studies of human populations exposed at those concentrations in drinking water that were useful for informing its assessment of potential neurologic effects. These studies were conducted in different areas of China, where fluoride concentrations ranged from 2.5 to 4 mg/L. Comparisons were made between the IQs of children from those populations with children exposed to lower concentration of fluoride ranging from 0.4 to 1 mg/L. The studies reported that while modal IQ scores were unchanged, the average IQ scores were lower in the more highly exposed children. This was due to fewer children in the high IQ range.”
Ellis 126
Rat studies suggest neurological effects
NRC (2006): Page 222:
“Long et al. (2002) reported changes in the number of acetylcholine receptors (nAChRs) in the rat brain due to fluoride. …These results are of interest because changes in the nicotinic receptors have been related to the development of Alzheimer’s disease (Lindstrom 1997; Newhouse et al. 1997) and, in frontal brain areas, to schizophrenia (Guan et al. 1999).”
Ellis 127
Conjecture #38
Fluoride causes Schizophrenia
See previous quote from NRC (2006) p. 221
Ellis 128
Conjecture #39 F is causally related to Goiter, an Iodine deficiency
Ellis 129
NRC, 2006, p.231.
Or less spectacularly in Nepal
Ellis 130
NRC, 2006, p.230.
Ellis 131
0
50
100
150
200
250
0 10,000 20,000 30,000 40,000 50,000 60,000 70,000
Au
stim
rat
e in
to
wn
per
10
,00
0
School Enrollment
Relationship Between Town School Enrollment and Rate of Autism, 2004-5, in 299 Massachusetts School Systems, Fluoridated and
UnFluoridate systems
Fluoridated Systems Unfluoridated Systems
Linear (Fluoridated Systems) Linear (Unfluoridated Systems)
Conjecture #40, 41
• High school and college teams in town with fluoridated water should have poorer success than those with unfluoridated water systems
• Professional sport teams with stadiums or arenas in areas without F should have better winning percentages than those in F regions.
Ellis 132
10 Facts and 41 Informed Conjectures about the Health Effects of Fluoride
Randall P. Ellis
Boston University
April 2016
Please to not quote or cite.
133